Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Pharm-Olam Selected as CRO for Phase 2 Lymphoma Study | Contract Pharma

What are you searching for?

Sign in
Breaking News

Pharm-Olam Selected as CRO for Phase 2 Lymphoma Study

Infinity Pharma previously partnered with the CRO for another Phase II study

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Pharm-Olam International, a multi-national, full-service clinical research organization (CRO) to the biopharmaceutical and medical device industries, has been selected as the CRO for Infinity Pharmaceuticals for the conduct of Infinity’s Fresco study, a Phase II clinical trial of an investigational medicine for the treatment of relapsed/refractory follicular lymphoma.

“We are extremely pleased to continue our collaboration with Infinity,” said Sanjiv Suri, chief executive officer, Pharm-Olam. “The Infinity team required a fast, flexible solution to provide a timely quality deliverable. It is a credit to our project teams that Infinity has decided to continue with Pharm-Olam as a part of its future clinical plans.”

Infinity previously partnered with Pharm-Olam for clinical, project management, medical monitoring, data management, and regulatory services for Dynamo, a Phase II study for patients with refractory indolent non-Hodgkin’s lymphoma (iNHL).

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics